REMEDY : BNSSG referral pathways & Joint Formulary

Home > Formulary : Adult > Chapters > 17. Miscellaneous Preparations >

BNSSG Adult Joint Formulary

17.1 Miscellaneous Preparations

Last edited: 04-06-2024

17.1 Miscellaneous Preparations

First line drugs Second line drugs Specialist drugs Secondary care drugs


All are TLS Red

Acid citrate dextrose

  • 500mL bags for use with Cell Saver machine
  • UHBW only

Autologous chondrocyte implantation

  • NICE TA477 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee
  • NICE TA508 Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee

Bone morphogenetic protein (Inductos®, Osigraft®)

  • N.B. Not for Complex spinal surgery - NHS England is the commissioner for this indication and they are not routinely commissioned.  An EFR application is required

Eleview® lifting solution

  • Lifting solution for endoscopic submucosal dissection (ESD) of polyps

Hexaminolevulinate (Hexvix) (TLS Red) 

  • To aid improved visualisation of bladder cancer
  • Tor use in patients with high or very high risk non-muscle invasive bladder cancer

Independence Wound Protection/Collection Pouch Covers:  VAP 1 (small), VAP 2 (regular), VAP 3 (large)

  • Dialysis pouch covers are not routinely recommended by renal dialysis teams, advise the patient to contact the dialysis team before purchasing covers

Lutetium (177Lu) oxodotreotide

  • NICE TA541 for treating unresectable or metastatic neuroendocrine tumours

Lutetium (177Lu) vipivotide tetraxetan

  • NHSE SCC 2362 for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes

Methoxsalen (Uvadex®)

  • For use by the Bristol Therapeutic Apheresis Unit for Photopheresis

N-acetylcisteine (NAC) mixed with simeticone

  • To improve mucosal visibility during upper GI endoscopy

Perflutren (Luminity®)

  • For ultrasound contrast-enhancing agent for use in adult patients as an alternative to SonoVue®

Regadenoson (Rapiscan®)

  • For use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress

Sulfur hexafluoride lipid microspheres (SonoVue®)

  • For use in Echocardiography, in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation
  • SonoVue® should only be used in patients where study without contrast enhancement is inconclusive

Sulfur hexafluoride lipid microspheres (SonoVue®)

  • For characterising indeterminate liver lesions, assessment of vascularity or blood flow for patients where an MRI or CT scan is unsuitable


  • For improvement of haemostatis in urology and cardiac surgery 



All medicines that are listed on the Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments are automatically included on the formulary as Red for use as per local Trust protocol. Please see RCEM guideline


Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.